RxDoctor Payments Data

Nathan Borgfeld, MD

Family Medicine · Seguin, TXNPI 1467801779

Payments from drug & device makers

$858in general payments, 2019–2025

Across 37 payments — averaging $23.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$248
  • Lilly USA, LLC$126
  • Genentech USA, Inc.$124
  • AstraZeneca$72
  • Access Pro Medical, LLC$48
  • Boehringer Ingelheim$38
  • plus $201 from 9 others

What the payments were for

  • Food & beverage$858100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$858 in reported general payments places this provider in the 55th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$228,359
Medicare patients
204
Services billed
3,110

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide176$182,138
OzempicSemaglutide115$117,319
FarxigaDapagliflozin Propanediol78$68,799
JardianceEmpagliflozin32$43,374
EliquisApixaban37$33,447
MyrbetriqMirabegron44$30,063
Budesonide ErBudesonide11$25,941
TrulicityDulaglutide23$22,408
JanuviaSitagliptin Phosphate25$20,349
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$17,391
XareltoRivaroxaban13$16,834
JubliaEfinaconazole18$15,141
GemtesaVibegron14$13,525
SymbicortBudesonide/Formoterol Fumarate39$8,586
Spiriva RespimatTiotropium Bromide14$7,645

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$126$204,546199 claims
Novo NordiskOzempic$248$117,319115 claims
AstraZenecaFarxiga, Symbicort$72$77,385117 claims
Boehringer IngelheimJardiance, Spiriva Respimat$38$51,01946 claims
MerckJanuvia$24$20,34925 claims
GSKTrelegy Ellipta$22$17,39126 claims
Sumitomo Pharma America, Inc.Gemtesa$15$13,52514 claims
AbbVieSynthroid$31$7,027102 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Seguin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →